Tags

Type your tag names separated by a space and hit enter

Pharmacodynamics OF TNF α inhibitors for the treatment of psoriasis.
Expert Opin Drug Metab Toxicol 2019; 15(11):913-925EO

Abstract

Introduction: The treatment of psoriasis with conventional topical therapies and disease-modifying anti-rheumatic drugs (DMARDs) is often linked to unsatisfactory outcomes and the risk of serious adverse events. Over the last decades, research advances in understanding the role of tumor necrosis factor alpha (TNF α) and other cytokines in the pathogenesis of psoriasis have driven the introduction of biologic agents targeting specific immune mediators in everyday clinical practice. TNF α inhibitors are a consolidated treatment option for patients with moderate-to-severe disease with remarkable efficacy and a reassuring safety profile.Areas covered: The PubMed database was searched using combinations of the following keywords: psoriasis, TNF α inhibitors, biologic therapy, pharmacodynamics, adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, adverse effects. The aim of this review is to describe the pharmacodynamic profile of anti-TNF α inhibitors, currently approved by the European Medicines Agency (EMA) for the treatment of psoriasis, focusing on related clinical implications, also in comparison to the new generation biological therapies targeting the interleukin 23/interleukin 17 axis.Expert opinion: Pharmacodynamics of TNF α inhibitors should be fully considered in planning patient's therapy strategies, especially in case of secondary failures, poor adherence to treatment, instable psoriasis, high risk of infection, pregnant or lactating women, metabolic comorbidities, coexistence of other immune-mediated inflammatory diseases.

Authors+Show Affiliations

Dermatological Clinic, Department of Clinical and Molecular Sciences, Polytechnic Marche University, Ancona, Italy.Dermatological Clinic, Department of Clinical and Molecular Sciences, Polytechnic Marche University, Ancona, Italy.Dermatological Clinic, Department of Clinical and Molecular Sciences, Polytechnic Marche University, Ancona, Italy.Dermatological Clinic, Department of Clinical and Molecular Sciences, Polytechnic Marche University, Ancona, Italy.Dermatological Clinic, Department of Clinical and Molecular Sciences, Polytechnic Marche University, Ancona, Italy.Dermatological Clinic, Department of Clinical and Molecular Sciences, Polytechnic Marche University, Ancona, Italy.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

31623470

Citation

Campanati, Anna, et al. "Pharmacodynamics of TNF Α Inhibitors for the Treatment of Psoriasis." Expert Opinion On Drug Metabolism & Toxicology, vol. 15, no. 11, 2019, pp. 913-925.
Campanati A, Paolinelli M, Diotallevi F, et al. Pharmacodynamics OF TNF α inhibitors for the treatment of psoriasis. Expert Opin Drug Metab Toxicol. 2019;15(11):913-925.
Campanati, A., Paolinelli, M., Diotallevi, F., Martina, E., Molinelli, E., & Offidani, A. (2019). Pharmacodynamics OF TNF α inhibitors for the treatment of psoriasis. Expert Opinion On Drug Metabolism & Toxicology, 15(11), pp. 913-925. doi:10.1080/17425255.2019.1681969.
Campanati A, et al. Pharmacodynamics of TNF Α Inhibitors for the Treatment of Psoriasis. Expert Opin Drug Metab Toxicol. 2019;15(11):913-925. PubMed PMID: 31623470.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Pharmacodynamics OF TNF α inhibitors for the treatment of psoriasis. AU - Campanati,Anna, AU - Paolinelli,Matteo, AU - Diotallevi,Frederico, AU - Martina,Emanuela, AU - Molinelli,Elisa, AU - Offidani,Annamaria, Y1 - 2019/10/29/ PY - 2019/10/19/pubmed PY - 2019/10/19/medline PY - 2019/10/19/entrez KW - Psoriasis KW - TNF-alpha inhibitors KW - adalimumab KW - adverse effects KW - biologic therapy KW - certolizumab pegol KW - etanercept KW - golimumab KW - infliximab KW - pharmacodynamics SP - 913 EP - 925 JF - Expert opinion on drug metabolism & toxicology JO - Expert Opin Drug Metab Toxicol VL - 15 IS - 11 N2 - Introduction: The treatment of psoriasis with conventional topical therapies and disease-modifying anti-rheumatic drugs (DMARDs) is often linked to unsatisfactory outcomes and the risk of serious adverse events. Over the last decades, research advances in understanding the role of tumor necrosis factor alpha (TNF α) and other cytokines in the pathogenesis of psoriasis have driven the introduction of biologic agents targeting specific immune mediators in everyday clinical practice. TNF α inhibitors are a consolidated treatment option for patients with moderate-to-severe disease with remarkable efficacy and a reassuring safety profile.Areas covered: The PubMed database was searched using combinations of the following keywords: psoriasis, TNF α inhibitors, biologic therapy, pharmacodynamics, adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, adverse effects. The aim of this review is to describe the pharmacodynamic profile of anti-TNF α inhibitors, currently approved by the European Medicines Agency (EMA) for the treatment of psoriasis, focusing on related clinical implications, also in comparison to the new generation biological therapies targeting the interleukin 23/interleukin 17 axis.Expert opinion: Pharmacodynamics of TNF α inhibitors should be fully considered in planning patient's therapy strategies, especially in case of secondary failures, poor adherence to treatment, instable psoriasis, high risk of infection, pregnant or lactating women, metabolic comorbidities, coexistence of other immune-mediated inflammatory diseases. SN - 1744-7607 UR - https://www.unboundmedicine.com/medline/citation/31623470/Pharmacodynamics_OF_TNF_α_inhibitors_for_the_treatment_of_psoriasis L2 - http://www.tandfonline.com/doi/full/10.1080/17425255.2019.1681969 DB - PRIME DP - Unbound Medicine ER -